Brequinar sodium significantly reduces the incidence of steroid-resistant rejection and resource utilization in primary renal transplant patients compared with azathioprine.
Dunn
J F
JF
University of California at San Diego, USA.
Hatch
J
J
Precht
A
A
Hart
M
M
Li
S
S
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology*; D007902:Length of Stay; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D010359:Patient Readmission; D011798:Quinaldines
D000961:Antilymphocyte Serum; D001379:Azathioprine; D001713:Biphenyl Compounds; D007166:Immunosuppressive Agents; D008775:Methylprednisolone; D016853:Muromonab-CD3; C046943:brequinar; D011798:Quinaldines